Clinical Trials Browser

INDUSTRY × Alpelisib × Breast × Clear all

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Advanced Breast Cancer

Advanced HER2+Breast Cancer

Breast Neoplasms

Breast Neoplasms

HER2-positive Metastatic Breast Cancer

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Endometrial Neoplasms

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Advanced Breast Cancer

Advanced or Metastatic ER+ Breast Cancer

Breast Neoplasms

Breast Neoplasms

Acrocephalosyndactylia, Breast Neoplasms

Breast Neoplasms, Head and Neck Neoplasms, Neoplasms

Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

Advanced Solid Tumors With an Alteration of the PIK3CA Gene

Pre-menopausal Breast Cancer

Breast Neoplasms

Breast Neoplasms, Ovarian Neoplasms

Clinical Trials

EPIK-B5

EPIK-B3

INAVO121

Managed Access Programs for BYL719, Alpelisib

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

EPIK-B2

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

SPEAR

VIKTORIA-1

BYLieve

ELEVATE

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

AMEERA-1

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

A Post Marketing Surveillance on Piqray in Korea

EMBER

SOLAR-1

EPIK-B4

BioItaLEE

TELEPIK

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

B-YOND

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors